Comparative liver toxicity of various erythromycin derivatives in animals
- 1 January 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 21 (suppl D) , 9-27
- https://doi.org/10.1093/jac/21.suppl_d.9
Abstract
The hepatotoxicity of a new erythrotnycin derivative, erythromycin acistrate (EA, 2′-acetyl erythromycin stearate), was compared with that of erythromycin stearate (ES), erythromycin estolate (EE) and erythromycin-11,12 cyclic carbonate (EC) in 4–5-day, 28-day and 6-month oral toxicity studies in rats and dogs. In the 4-day rat study, EC caused fatty metamorphosis in the liver. ES caused similar, but milder changes at a dose nearly five times higher. The 5-day dog study revealed markedly increased serum alanine aminotransferase (S-ALAT), serum aspartate aminotransferase (S-ASAT), serum alkaline phosphatase (S-APHOS) and serum γ-glutamyl transpeptidase (S-γ-GT) values in the EC- and EE-groups, and slightly elevated S-ALAT values also in the EA- and ES-groups. Microscopy revealed cholangitis, pericholangitis and phlebitis in the portal areas in the EC-group at all doses. Epithelial hyperplasia was observed also in the bile ducts. EE caused similar but milder changes. The changes in the EA-group were small, but mildly atypical bile duct epithelium was seen in female dogs receiving 2 × 200 mg/kg of EA. The ES-group was practically without changes and very much like the EA-group. Thus the dog proved to be a more sensitive model for assessing the hepatotoxicity of erythromycin derivatives. In the 28-day studies, only EA and ES were investigated. In the rat study, slightly elevated serum enzyme levels within the normal range were measured in the high-dose regimens of both drugs. In the dog study, 300 mg/kg of EA caused slightly elevated S-ALAT in males, but the values returned to normal after a 2-week off-dose period. Only EA was studied in the 6-month study. In male rats, 400 mg/kg of EA caused slightly elevated enzyme levels and neutral fat droplets in centrilobular hepatocytes. In male dogs given 150 mg/kg of EA, S-ALAT, S-APHOS, and S-γ-GT values were elevated after four weeks of treatment but returned to normal thereafter. No severe changes were seen in the liver histopathology. In conclusion, EC and EE were clearly hepatotoxic in dogs, and EC also in rats. EA, and to a somewhat lesser extent ES, showed signs of mild hepatotoxicity only at high doses. This evidently reversible effect was considered a common characteristic of erythromycins.Keywords
This publication has 9 references indexed in Scilit:
- Subchronic Toxicity of some Erythromycin Compounds in RatsActa Pharmacologica et Toxicologica, 2009
- Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitisJournal of Antimicrobial Chemotherapy, 1988
- Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting stateJournal of Antimicrobial Chemotherapy, 1988
- Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteersJournal of Antimicrobial Chemotherapy, 1988
- Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liverToxicology and Applied Pharmacology, 1985
- Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparationsBiochemical Pharmacology, 1978
- Erythromycin: A review of its uses in pediatric practiceThe Journal of Pediatrics, 1976
- Chemical Structure of Erythromycin and HepatotoxicityAnnals of Internal Medicine, 1974
- Further toxicological studies with ilotycin® (Erythromycin, Lilly)Journal of the American Pharmaceutical Association (Scientific ed.), 1955